JPMorgan analyst Tessa Romero initiated coverage of Oculis (OCS) with an Overweight rating and $38 price target The firm says Oculis has a diversified ophthalmology pipeline with “multiple shots on goal” in eye indications with high unmet need. The company’s most advanced asset OCS-01 has shown “supportive” efficacy and safety in diabetic macular edema with its non-invasive and patient-friendly eye drop approach, the analyst tells investors in a research note. JPMorgan sees the shares as well positioned for upside as Oculis generates additional data.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis initiated with an Outperform at LifeSci Capital
- Oculis price target lowered to $29 from $30 at BofA
- 3 Best Stocks to Buy Now, 11/11/2025, According to Top Analysts
- Oculis price target raised to $42 from $36 at H.C. Wainwright
- Oculis Holding: Promising Pipeline Developments and Strong Financial Position Support Buy Rating